Literature DB >> 16249543

Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study.

Antonio E Pontiroli1, Franco Folli, Michele Paganelli, Giancarlo Micheletto, Pierluigi Pizzocri, Paola Vedani, Francesca Luisi, Lucia Perego, Alberto Morabito, Santo Bressani Doldi.   

Abstract

OBJECTIVE: Lifestyle modifications and pharmacological interventions can prevent type 2 diabetes in obese subjects with impaired glucose tolerance. The aim of this study was to compare laparoscopic adjustable gastric banding (LAGB) and conventional diet (No-LAGB) in the prevention (primary intervention study; 56 vs. 29 patients) and remission (secondary intervention study; 17 vs. 20 patients) of type 2 diabetes and hypertension in grade 3 obesity in a 4-year study. RESEARCH DESIGN AND METHODS: The subjects (n = 122; age 48.5 +/- 1.05 years; BMI 45.7 +/- 0.67 kg/m2) underwent a diagnostic workup, including psychological and psychiatric assessments, in preparation for the LAGB procedure. Of the 122 subjects, 73 had the surgery (LAGB group). The control group (No-LAGB group) consisted of the 49 subjects who refused the surgery but agreed to be followed up; 6 of these subjects dropped out by the 2nd year of the study, so that the final number of patients was 73 and 43 in the LAGB and No-LAGB groups, respectively. All patients had a yearly visit and oral glucose tolerance test.
RESULTS: From baseline to the end of the 4-year follow-up, BMI decreased from 45.9 +/- 0.89 at baseline to 37.7 +/- 0.71 kg/m2 in the LAGB group and remained steady in the No-LAGB group (from 45.2 +/- 1.04 to 46.5 +/- 1.37 kg/m2), with no significant differences between the primary and secondary intervention groups. In the primary intervention study, five of the No-LAGB subjects (17.2%) and none of the LAGB subjects (0.0%; P = 0.0001) progressed to type 2 diabetes; in the secondary intervention study, type 2 diabetes remitted in one No-LAGB patient (4.0%) and seven LAGB patients (45.0%; P = 0.0052). Hypertension occurred in 11 No-LAGB patients (25.6%) and 1 LAGB patient (1.4%; P = 0.0001) and remitted in 1 No-LAGB (2.3%) and 15 LAGB patients (20.5%; P = 0.0001). A study of body mass composition revealed a significant reduction of fat mass and a transitory, but not significant, decrease of fat-free mass in LAGB patients.
CONCLUSIONS: In morbid obesity, sustained and long-lasting weight loss obtained through LAGB prevents the occurrence of type 2 diabetes and hypertension and decreases the prevalence of these disorders.

Entities:  

Mesh:

Year:  2005        PMID: 16249543     DOI: 10.2337/diacare.28.11.2703

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  33 in total

Review 1.  Metabolic surgery for the treatment of type 2 diabetes in patients with BMI <35 kg/m2: an integrative review of early studies.

Authors:  M Fried; G Ribaric; J N Buchwald; S Svacina; K Dolezalova; N Scopinaro
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

2.  Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding.

Authors:  Lotte Usinger; Katrine B Hansen; Viggo B Kristiansen; Steen Larsen; Jens J Holst; Filip K Knop
Journal:  Obes Surg       Date:  2011-05       Impact factor: 4.129

Review 3.  The growing role of bariatric surgery in the management of type 2 diabetes: evidences and open questions.

Authors:  Luca Busetto; Paolo Sbraccia; Lucia Frittitta; Antonio E Pontiroli
Journal:  Obes Surg       Date:  2011-09       Impact factor: 4.129

4.  Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia.

Authors:  H M Heneghan; S Nissen; P R Schauer
Journal:  Curr Atheroscler Rep       Date:  2012-12       Impact factor: 5.113

5.  Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

Authors:  D M Nathan; J B Buse; M B Davidson; R J Heine; R R Holman; R Sherwin; B Zinman
Journal:  Diabetologia       Date:  2006-08       Impact factor: 10.122

6.  Immune cell-mediated inflammation and the early improvements in glucose metabolism after gastric banding surgery.

Authors:  Katherine Samaras; Alexander Viardot; Natalia K Botelho; Alicia Jenkins; Reginald V Lord
Journal:  Diabetologia       Date:  2013-09-13       Impact factor: 10.122

7.  Relation of fasting plasma peptide YY to glucose metabolism and cardiovascular risk factors after restrictive bariatric surgery.

Authors:  Ursula Hanusch-Enserer; Mohammed A Ghatei; Edmund Cauza; Steven R Bloom; Rudolf Prager; Michael Roden
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

8.  Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding.

Authors:  Amalia Gastaldelli; Lucia Perego; Michele Paganelli; Giorgio Sesti; Marta Hribal; Alberto O Chavez; Ralph A Defronzo; Antonio Pontiroli; Franco Folli
Journal:  Obes Surg       Date:  2008-09-24       Impact factor: 4.129

Review 9.  Impact of surgical and nonsurgical weight loss on diabetes resolution and cardiovascular risk reduction.

Authors:  Katherine E Nori Janosz; Kerstyn C Zalesin; Wendy M Miller; Peter A McCullough; Barry A Franklin
Journal:  Curr Diab Rep       Date:  2009-06       Impact factor: 4.810

10.  Benchmarking hospital outcomes for laparoscopic adjustable gastric banding.

Authors:  M A Edwards; R Grinbaum; B E Schneider; A Walsh; J Ellsmere; D B Jones
Journal:  Surg Endosc       Date:  2007-05-05       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.